



ASX ANNOUNCEMENT

30 August 2024

Cann Group Receives \$1 Million Advance on R&D Refund

30 August 2024 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that it has received an advance of \$1 million (**Advance**) from Endpoints Capital Pty Limited (**Endpoints**), providing early access to the Company's expected Research and Development (R&D) Tax Incentive for FY2024 of \$1.965 million (**R&D Refund**).

The Advance was provided under the terms of a loan agreement executed between Cann and Endpoint (the **Loan Facility**). The Advance incurs an interest rate of 16.0% per annum, calculated daily, with a minimum interest period of 90 days, which will be repaid on the date that proceeds of the R&D Refund are received, or by 30 November 2024 (whichever occurs earlier).

Jenni Pilcher, CEO & Managing Director states: "The Advance provides Cann with immediate funding to support the operation of the business, including the important R&D activities of which R&D Refund was based which supports Cann's goal of supplying in the market medicinal cannabis products, based on unique strains and delivery methods."

Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com

About Endpoints Capital

Endpoints Capital Pty Limited (ABN 25 671 248 525) is an Australian-based R&D finance firm that specializes in providing financing solutions for biotechnology and healthcare companies accessing the Australian research & development tax incentive scheme. Endpoints' mission is to address the

funding challenges faced by biotechs and medtechs, allowing them to focus on innovation and development. As an Australian private company with 30 years of life sciences experience, Endpoints Capital plays a crucial role in supporting the growth of the lifesciences industry in Australia.
Learn more at: <https://endpointscapital.com.au/>